(S)-2-Amino-4,5,6,7-Tetrahydro-6-(Propylamino)Benzothiazole

Why the free base, not a pre-formed salt, is preferred for controlled crystallization under cGMP

In the synthesis train of pramipexole dihydrochloride monohydrate, the (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole free base is isolated prior to salification rather than crystallizing the dihydrochloride directly from the reductive amination milieu. This upstream decision is driven by the requirement to purge the 0.15% (R)-enantiomer that typically survives asymmetric hydrogenation over a chiral Ru-BINAP catalyst system at 40–60 bar H₂ and 50–65°C. The free base, having a pKa₁ of ~4.8 (benzothiazole N) and pKa₂ of ~9.8 (propylamino side chain), is extracted into dichloromethane at pH 10–11 where the (R)-isomer partitions differently when a fractional crystallization of the free base from n-heptane/ethyl acetate (85:15 v/v) is employed. Liquid chromatography data logged on a Chiralpak IA-3 column (250 × 4.6 mm, 3 µm) with n-hexane/ethanol/diethylamine 90:10:0.1 mobile phase at 1.0 mL/min routinely demonstrates enantiomeric excess exceeding 99.85% after a single recrystallization. Equipment on the pilot scale involves a glass-lined reactor with a retreat-curve impeller maintaining a tip speed below 2.5 m/s to limit nucleation-induced lattice strain that could entrap the distomer. The free base is then charged into the subsequent salt-formation vessel as a crystalline solid with residual solvent limits conforming to ICH Q3C Class 2 thresholds—dichloromethane below 600 ppm, n-heptane below 5000 ppm.

The salification process itself uses a stoichiometric amount of concentrated hydrochloric acid (37% w/w, 1.98 equivalents relative to the free base) dispensed with a mass flow controller into an isopropanol/water (92:8 w/w) suspension of the free base at 15–20°C. A feedback loop driven by an in-line FTIR probe tracks the disappearance of the free-base imine stretch at 1638 cm⁻¹ and the concomitant growth of the protonated ammonium band at 2600–2500 cm⁻¹. Once the target pH of 2.3–2.7 is reached, the batch is seeded with micronized pramipexole dihydrochloride monohydrate (0.5 wt% of theoretical yield, d₉₀ ≤ 20 µm) to direct the formation of the monohydrate polymorph as defined by Powder X-ray Diffraction peaks at 2θ = 8.9°, 15.2°, 21.7° (Cu Kα). Cooling to 0–5°C at a linear ramp of 0.15°C/min yields a crop that is washed with chilled acetone and vacuum-dried at 40°C (≤ 10 mbar) until Karl Fischer titration returns a water content of 6.0–6.5% w/w, matching the theoretical monohydrate value of 6.21%. Final compliance with USP-NF Pramipexole Dihydrochloride Monohydrate monograph and Ph.Eur. 10.5 is verified through assay by potentiometric titration against 0.1N perchloric acid in anhydrous formic acid/acetic anhydride, loss on drying, and chiral purity by the method above.

For immediate-release solid dosage forms listed in the FDA Orange Book under RLD NDA 020667, the microcrystalline free base is not handled; instead, the pre-formed, milled pramipexole dihydrochloride monohydrate is geometrically blended with a diluent-filler system before being charged into a diffusion mixer. Direct compression consistently fails at dose strengths of 0.125 mg and 0.25 mg per tablet because the active particle count per compression station is too low to meet USP <905> uniformity criteria when using ordered mixing alone. The established workaround on production suites employing a Fette 102i rotary press with 36 stations is to pre-blend the API with microcrystalline cellulose (Avicel PH-102, 47.5% w/w of total core) that has been pre-conditioned at 25°C/35% RH for 48 hours to equilibrate its moisture to 3.5–4.0%, then add mannitol (Pearlitol SD 200, 28.0% w/w), pregelatinized starch (Starch 1500, 22.0% w/w), colloidal silicon dioxide (0.5% w/w), and magnesium stearate (1.5% w/w) screened through a 500 µm sieve. Blend uniformity samples taken at 10, 15, and 20 minutes from a 600 L Bohle bin blender running at 10 rpm must yield an RSD ≤ 4.0% by HPLC-UV detection at 262 nm before tablet compression proceeds with a target hardness of 40–60 N and a disintegration time of < 5 min in 900 mL water at 37°C per USP <701>. Tablets are typically film-coated with Opadry II white using a perforated side-vented pan achieving a weight gain of 2.5–3.5%.

Extended-release matrix tablets and the critical dependence on propylamino side-chain hydration state

Once-daily formulations governed by NDA 022421 (Mirapex ER) demand a hydrogel matrix that retards erosion sufficiently to extend the mean residence time of a highly water-soluble active—pramipexole dihydrochloride solubility exceeds 200 mg/mL in water. The matrix former chosen is hypromellose (HPMC K4M, apparent viscosity 2663–4975 mPa·s as a 2% aqueous solution at 20°C) combined with HPMC K100M (75000–140000 mPa·s) at a ratio of 1.3:1. A high-shear wet granulation step is mandated because direct compression of such high-viscosity polymers with a low-dose API (0.375 mg, 0.75 mg, 1.5 mg, 3.0 mg, 4.5 mg) leads to segregation of the light active particles from the denser HPMC during tablet press hopper vibration. In the granulator bowl (Gral 150 with chopper at 1500 rpm), the active is dissolved in purified water along with povidone K30 (3.0% of dry granulate mass) to serve as the binder solution, which is sprayed onto the HPMC/colloidal silicon dioxide pre-mix. This method ensures that pramipexole molecules are molecularly deposited onto polymer surfaces, eliminating the risk of dose content variations that otherwise exceed 6% RSD after 30 minutes of blending. After drying in a Glatt fluidized bed at inlet air temperature 65°C to LOD < 2.0%, the granules are milled through a 1.0 mm screen and lubricated with sodium stearyl fumarate (1.2%) instead of magnesium stearate to avoid hydrophobic retardation interference with the HPMC hydration front. Tablets are compressed to a target thickness of 4.8–5.2 mm for the 1.5 mg strength, with breaking force maintained at 100–140 N to achieve a friability below 0.2%.

Dissolution testing follows USP monograph method using Apparatus I (baskets) at 100 rpm in 500 mL of pH 6.8 phosphate buffer. The required release windows are established tightly: not less than 20% of labeled content at 1 hour, 40–65% at 4 hours, and not less than 80% at 12 hours. Failure modes on industrial-scale batches have been correlated to HPMC particle-size drift; when the d₅₀ of K4M shifts from the specified 90–150 µm to below 70 µm, release accelerates beyond the 65% limit at 4 hours due to a larger surface area of wetted polymer. This sensitivity forces incoming lot checks by laser diffraction (Malvern Mastersizer 3000 with dry dispersion at 2 bar) and demands that the granulation endpoint be strictly controlled by impeller power consumption (± 5% from baseline). Storage under accelerated conditions (40°C/75% RH) consistently shows an upward drift in dissolution rate after 6 months if the tablets are packaged in HDPE bottles without desiccant; the pramipexole moiety remains chemically stable (< 0.2% total impurities), but the HPMC matrix undergoes limited syneresis that reduces gel layer thickness by approximately 12% as measured by optical coherence tomography.

Investigational transdermal delivery platforms seek to bypass the 90% oral bioavailability characteristic of pramipexole and target constant plasma levels in the range of 100–500 pg/mL for restless legs syndrome maintenance. The (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole free base, not the hydrochloride salt, is the candidate species for pressure-sensitive adhesive (PSA) matrices because its logP of 0.8 and its unionized fraction at skin surface pH 4.5–5.5 determine the flux across human cadaver epidermis. A typical formulation coats a polyester release liner with a solution of DURO-TAK 87-428A acrylic PSA in ethyl acetate, the free base dissolved at 2.5% w/w of dry adhesive, alongside oleic acid (10% w/w of adhesive) as a percutaneous penetration enhancer. Franz-type diffusion cells with a receptor compartment filled with phosphate-buffered saline at pH 7.4 containing 0.01% gentamicin and maintained at 32°C yield steady-state flux values of 0.5–1.2 µg/cm²/h depending on donor concentration. The manufacturing coating and drying process on a Mathis coating table with a knife-over-roll applicator demands a drying regime of 60°C/30 min followed by 80°C/10 min to remove residual ethyl acetate below 100 µg/g as verified by headspace GC-FID. A critical incompatibility emerges in the adhesive formulation: prolonged contact of the free base with the carboxyl functional groups of the acrylic PSA at elevated drying temperatures catalyzes partial amide formation, reducing the active loading by 4–7% after 3 months at 25°C. This is suppressed by pre-neutralizing 15% of the adhesive’s carboxylic acid sites with sodium hydroxide before drug addition, a modification that sacrifices no tack (loop tack maintained at ≥ 8 N/25 mm per PSTC-16) while stabilizing the amine against nucleophilic addition.

A separate application stream focuses on the use of (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole as the primary reference standard and its structurally related compounds as system suitability markers in pharmacopoeial quality control testing. The USP Pramipexole Dihydrochloride Monograph RS specifies the free base under catalog number 1557008 with a purity assignment by mass balance (loss on drying, residue on ignition, residual solvents, HPLC purity at 254 nm) traceable to the USP reference standard program. During inorganic impurity profiling by inductively coupled plasma mass spectrometry (ICP-MS) per USP <233>, the free base is reconstituted in 2% nitric acid and analyzed for Class 1 and Class 2A elements with reporting thresholds of 0.1 µg/g for palladium (catalyst carryover) and 0.5 µg/g for iron. The standard is also used to calibrate the organic impurity panel: (R)-enantiomer at RRT 1.1, 2-amino-4,5,6,7-tetrahydro-6-propionylaminobenzothiazole at RRT 1.4, and the des-propyl analog at RRT 0.7. A YMC-Pack Pro C18 column (150 × 4.6 mm, 3 µm) operating at 30°C with a gradient of methanol and pH 3.5 phosphate mobile phase resolves the critical pair between pramipexole and its N-oxide degradation product with a resolution of ≥ 2.0. In robustess studies, organic modifier percentage variations of ± 2% shift retention times by 0.4 min but maintain resolution above the system suitability minimum of 1.5. For chemical reference substance certification under ISO Guide 34:2009, differential scanning calorimetry (DSC) at 10°C/min under nitrogen shows a single endothermic event with an onset of 286.5 ± 0.5°C corresponding to the melting of the monohydrate form, and thermogravimetric analysis confirms the water loss step between 120°C and 160°C of exactly 6.2%.

The following table compiles the impurity limits applied during the release testing of pramipexole dihydrochloride monohydrate API against current pharmacopoeial thresholds. Each entry is anchored to a specific gas or liquid chromatographic method described in the USP-NF 2024 issue.

How nasal in situ gel systems exploit the free base’s amino-propyl pharmacophore for trigeminal nerve targeting

Intranasal delivery of the free base directly to the cribriform plate region has been investigated as a strategy to achieve cerebrospinal fluid concentrations exceeding those attainable with oral pramipexole while avoiding peripheral dopaminergic side effects. The formulation vehicle usually is a thermoreversible poloxamer 407 (18% w/v) and poloxamer 188 (2% w/v) matrix that transitions from a liquid at 4°C to a gel at nasal cavity temperature (32–34°C). The free base is charged at a concentration of 5 mg/mL after pH adjustment to 5.5–6.0 with 0.1M HCl, a range that balances mucosal tolerability against the ionized fraction needed for aqueous solubility. Verifying mucociliary clearance interference is mandatory: frog palate ciliary beat frequency assays generally tolerate exposure times up to 60 minutes before a drop in beat frequency below 80% of control is recorded. Spray characterization by laser light diffraction (Spraytec, Malvern) demands a Dv₅₀ of 25–40 µm when actuated through a metered-dose nasal pump delivering 100 µL per puff; particles below 10 µm raise concerns about pulmonary deposition and must be limited to < 5% of the total volume. Preclinical data published on this specific configuration remains limited, but initial pharmacokinetic reports in rodent models cite a CSF-to-plasma pramipexole concentration ratio above 3.0 at 30 minutes vs. 0.2 for oral administration, a difference attributed entirely to the avoidance of P-glycoprotein efflux at the blood-brain barrier.

The free base crystalline material is also repurposed as a chiral building block in the synthesis of isotopically labeled internal standards for LC-MS/MS bioanalytical assays. Deuterium incorporation at the propylamino side chain, specifically at the β-carbon position, is achieved by reductive amination of the tetrahydropyrrole intermediate with propionaldehyde-d₆ under sodium cyanoborohydride conditions, yielding (S)-2-amino-4,5,6,7-tetrahydro-6-(propyl-d₇-amino)benzothiazole. The reaction is conducted in anhydrous methanol with rigorous exclusion of atmospheric moisture because the imine intermediate is water-labile, driving the equilibrium backward and reducing deuteration efficiency below the 98% acceptance threshold. Post-reaction purification by preparative HPLC on a C18 column with acetonitrile/water/trifluoroacetic acid 0.05% delivers a product with isotopic purity exceeding 99.5% and a chemical purity of 99.8%. This deuterated standard is critical for the quantitative bioanalysis of pramipexole in human plasma by turbo ion spray tandem mass spectrometry, where the lower limit of quantification defined at 50 pg/mL per FDA bioanalytical method validation guidance requires a stable internal standard with less than 0.1% unlabeled analog cross-contamination. The analytical column switched to a Phenomenex Kinetex F5 (50 × 2.1 mm, 2.6 µm) operated at 0.4 mL/min with mobile phases of 10 mM ammonium formate pH 3.0 and methanol, monitoring the MRM transition 212.1 → 153.1 for the analyte and 219.2 → 153.1 for the deuterated analog. Injecting the free base standard in solvent demonstrates no isobaric interference at the retention time window 2.7 ± 0.1 min.

An additional niche exists in veterinary pharmacopeia where the monohydrochloride salt of (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole has been evaluated as an adjunctive treatment for canine compulsive disorders. Published data from open-label trials in 12 dogs at doses of 0.05 mg/kg orally twice daily with a titration schedule of 0.02 mg/kg increments every 7 days indicate a statistically significant reduction in the global severity score of Canine Compulsive Scale. The veterinary compounding pharmacy receives the free base and converts it to a flavored suspension using Ora-Plus/Ora-Sweet vehicle at a final concentration of 0.25 mg/mL. Stability of the compounded suspension is verified at 4°C and 25°C for 90 days by HPLC-UV; beyond 14 days at room temperature, a 3% drop in potency is observed, mandating refrigerated storage and a beyond-use date of 30 days per USP <795>. The container closure is an amber polyethylene terephthalate bottle with a child-resistant adapter because pramipexole is known to trigger emesis at doses exceeding 0.1 mg/kg in canines, making overdose safety a primary packaging concern.